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DOI 10.1186/s13014-015-0385-9RESEARCH Open AccessMulticriteria optimization enables less
experienced planners to efficiently produce high
quality treatment plans in head and neck cancer
radiotherapy
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Roel JHM Steenbakkers1 and Erik W Korevaar1Abstract
Objectives: To demonstrate that novice dosimetry planners efficiently create clinically acceptable IMRT plans for
head and neck cancer (HNC) patients using a commercially available multicriteria optimization (MCO) system.
Methods: Twenty HNC patients were enrolled in this in-silico comparative planning study. Per patient, novice
planners with less experience in dosimetry planning created an IMRT plan using an MCO system (RayStation).
Furthermore, a conventionally planned clinical IMRT plan was available (Pinnacle3). All conventional IMRT and MCO-plans
were blind-rated by two expert radiation-oncologists in HNC, using a 5-point scale (1–5 with 5 the highest score)
assessment form comprising 10 questions. Additionally, plan quality was reported in terms of planning time, dosimetric
and normal tissue complication probability (NTCP) comparisons. Inter-rater reliability was derived using the intra-class
correlation coefficient (ICC).
Results: In total, the radiation-oncologists rated 800 items on plan quality. The overall plan score indicated no differences
between both planning techniques (conventional IMRT: 3.8 ± 1.2 vs. MCO: 3.6 ± 1.1, p = 0.29). The inter-rater reliability of
all ratings was 0.65 (95% CI: 0.57–0.71), indicating substantial agreement between the radiation-oncologists. In 93% of
cases, the scoring difference of the conventional IMRT and MCO-plans was one point or less. Furthermore, MCO-plans led
to slightly higher dose uniformity in the therapeutic planning target volume, to a lower integral body dose
(13.9 ± 4.5 Gy vs. 12.9 ± 4.0 Gy, p < 0.001), and to reduced dose to the contra-lateral parotid gland (28.1 ± 11.8 Gy vs.
23.0 ± 11.2 Gy, p < 0.002). Consequently, NTCP estimates for xerostomia reduced by 8.4 ± 7.4% (p < 0.003). The hands-on
time of the conventional IMRT planning was approximately 205 min. The time to create an MCO-plan was on average
43 ± 12 min.
Conclusions: MCO planning enables novice treatment planners to create high quality IMRT plans for HNC patients.
Plans were created with vastly reduced planning times, requiring less resources and a short learning curve.
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For patients with head and neck cancer (HNC), intensity-
modulated radiotherapy (IMRT) has been demonstrated to
reduce radiation induced complications, as compared to
conventional radiation delivery techniques [1,2]. IMRT al-
lows for dose distributions with curative intended dose to
tumor tissue, with an attempt to minimize dose to organs
at risk (OARs) related to late toxicities, such as xerostomia
and dysphagia [3,4].
The trade-offs between the target(s) and the relative
large number of OARs in the head and neck area cause
the conventional treatment planning procedure to be
cumbersome. The creation of a conventional IMRT plan
requires an iteration loop of changing patient specific
trade-off objectives and dose re-computations, and is
therefore subjective. Subtle changes in one of the
optimization parameters potentially yield profound effects
to the overall dose distribution quality. Furthermore, con-
ventional IMRT increases the planning time and contains
a relatively long learning curve [5-7]. The transition from
IMRT to VMAT could further increase planning times
due to longer calculation times in VMAT planning. The
increasing demand of IMRT and VMAT plans, however,
requires efficient departmental workflows.
Recently, multicriteria optimization (MCO) has become
commercially available for IMRT [8]. With MCO, a library
of Pareto optimal plans is generated automatically empha-
sizing different trade-off objectives. Each library plan is op-
timal in a way that one objective can only be improved by
deteriorating on others. The final treatment plan can be se-
lected by interactively navigating across the pre-computed
Pareto plans from which a deliverable plan is created.
Previous studies have demonstrated that MCO results
in treatment plans that are superior in terms of planning
time and dose distributions as compared to conventional
IMRT plans [9-14]. Craft et al. demonstrated that with
MCO, high quality IMRT plans for glioblastomas and
pancreatic cancers can be created more efficiently [9].
Using MCO for prostate cancers, significant reductions
in rectal dose were demonstrated by McGarry et al. [13].
However this came, to some extent, at the expense of
less conformal tumor dose distributions and higher dose
to the bladder. Voet et al. showed that fully automatic-
ally generated IMRT plans for HNC were superior in
terms of improved plan quality and reduced workload,
and were in 97% of cases selected by physicians in favor
of manually generated IMRT plans [10]. Their study
used prioritized optimization, resulting in one treatment
plan only, and not requiring manual Pareto surface
navigation.
Last years, the demand for IMRT has grown exponen-
tially: for multiple treatment sites as well as in-silico
planning comparative studies. To efficiently use depart-
mental resources, while striving for high plan quality, wetested the hypothesis that less experienced dosimetry
planners create clinically acceptable IMRT plans with a
commercially available MCO system as good as conven-
tional IMRT plans created by experienced planners.
Therefore, twenty HNC patients previously treated with
conventional IMRT were included in this study. Plan
quality was reported in terms of planning time, dosimetric
and normal tissue complication probability (NTCP) com-
parisons, and blinded plan ratings, performed by two
radiation-oncologists (RO) expert in HNC radiotherapy
(H.B. and R.S.).
Methods and materials
Patients, prescriptions and delineation
The study cohort consisted of twenty patients, of which
11 males and 9 females (median age 58; range: 46–65),
diagnosed with stage II-IV squamous cell carcinoma of
the head and neck, which were successively selected
from a database of HNC patients included in a prospect-
ive standard follow up program. Patients were included
with tumors originating in the retromolar trigonum,
base of tongue, tonsillar region, soft palate, nasopharynx,
piriform sinus, supraglottic larynx, and glottis larynx. All
patients were previously treated with curatively intended
radiotherapy (conventionally planned IMRT) either
alone or combined with concomitant chemotherapy or
cetuximab.
For each patient, a simultaneous integrated boost tech-
nique was planned comprising a total dose of 70 Gy to
the planning target volume (PTVboost, in 2 Gy per fraction,
5 fractions per week and 7 weeks) and 54.25 Gy to the
prophylactic PTV (PTVprophylactic, in 1.55 Gy per fraction).
Both PTVs were created with 5 mm margins to the clinical
target volume to account for geometrical uncertainties in
the treatment process.
For treatment planning optimization, the brain, spinal
cord and parotid glands were contoured. Additionally,
ring structures of 1 and 6 cm around PTVprophylactic were
constructed to ensure steep dose fall-off between the
PTVs and surrounding OARs. For planning evaluation,
the following OARs related to swallowing dysfunction
were contoured (according to guidelines described else-
where [15]): the supraglottic larynx, pharyngeal con-




The clinically delivered IMRT plans were created by
multiple experienced planners (minimal 5 years experi-
ence) using the Pinnacle3 treatment planning system
(TPS) (version 9.0, Philips Healthcare, Andover, MA).
All plans consisted of seven equispaced beams and were
prioritized optimized in two steps. First, each plan was
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to the dose level prescriptions, without exceeding the
maximum dose to the spinal cord and brain, which were
constrained to 50 Gy and 60 Gy, respectively. Second, the
dose to the parotid glands was reduced without deteriorat-
ing on target coverage. The most relevant IMRT parame-
ters set were: a dose grid resolution of 0.4 × 0.4 × 0.2 cm3;
maximum number of segments 84; minimum four moni-
tor units per segment; minimum segment area four cm2;
optimization type DMPO (direct machine parameter
optimization); and a final adaptive convolution dose com-
putation. In DMPO the conversion step of a fluence-based
plan to a segmented machine deliverable plan is integrated
in the optimization. This improves IMRT planning by
avoiding deterioration of the dose distribution of a
sequential fluence optimization followed by conversion to
segments. During optimization, however, a fast approxi-
mate dose calculation method is applied which requires a
clinical (adaptive convolution) dose calculation after the
optimization has finished.MCO planning
Three novice planners with no experiences in IMRT
planning and minimal instruction to IMRT created the
MCO-plans using the RayStation TPS (research version
2.4.11, RaySearch Laboratories AB, Stockholm). The
software was installed on a 64-bit Windows desktop
computer with an Intel Xeon 2.4 GHz processor and
24GB DDR3 RAM. Per plan, the same structure defini-
tions were used as for the conventional IMRT plans. A
template with n tradeoff objectives and constraints was




1: Dose hot spots in PTVboost 4.7 (0.5)
2: Dose hotspots in PTVprophylactic 4.4 (0.9)
3: Dose cold spots in PTVboost 3.9 (0.9)
4: Dose cold spots in PTVprophylactic 4.0 (1.2)
5: Conformity of 95% isodose around PTVboost 3.8 (1.0)
6: Conformity of 95% isodose around PTVprophylactic 4.0 (1.1)
7: Maximum dose to spinal cord 4.9 (0.5)
8: Parotid gland dose 4.4 (0.7)
9: Dose in unspecified tissue 4.0 (0.8)
10: General plan quality 3.8 (1.2)
Total 41.7 (6.4)
The plan quality scores range from 1–5 with 5 the highest score. Abbreviations: IMR
planning target volume, SD standard deviation, ICC intra-class correlation coefficien
p < 0.005; Bonferroni correction with α = 0.05/10 questions.plans, to input the MCO. A library of 2n plans was cre-
ated based on this template. During the first n plans,
each objective was optimized individually and these were
denoted as the anchor plans. The (n + 1)th plan is the
balanced plan in which all objectives were partially con-
sidered. The additional plans were the so-called auxiliary
plans and constructed towards improving the Pareto sur-
face as much as possible [8]. The final dose distribution
was selected by navigation across the Pareto surface
using slider bars on clinical objectives. A list with clinical
criteria was used during navigation that included criteria
for minimum and maximum dose in the targets and
maximum dose to organs at risk like the spinal cord. A
table with colored markers visually showed which cri-
teria were fulfilled so that the majority of clinically un-
acceptable plans could be avoided. No ROs were
involved in the final plan selection. Hence, a deliverable
plan was created by direct aperture optimization, using
similar IMRT parameters as in the conventional IMRT
plans (a dose grid resolution of 0.3 × 0.3 × 0.3 cm3; max-
imum number of segments 84; minimum four monitor
units per segment; minimum segment area four cm2)
and a final collapsed cone dose computation.Plan evaluation
All Pinnacle3 plans were exported to the RayStation system.
For each patient, the conventional IMRT and MCO-plans
were independently evaluated and blind-rated by two ex-
perts RO in HNC (H.B. and R.S.). Plan rating was per-
formed using an in-house-developed assessment form,
including 5-point scales [poor (1) – excellent (5)] for the
following items (Table 1):ality scores and the inter-rater reliability
RT MCO
Mean (SD) p-value ICC agreement (95% CI)
4.7 (0.5) 1.00 0.26 (−0.36 – 0.6)
4.6 (0.5) 0.15 0.51 (0.28 – 0.79)
3.5 (0.9) 0.01 0.57 (0.22 – 0.77)
3.9 (1.1) 0.45 0.70 (0.45 – 0.84)
3.5 (0.8) 0.11 0.19 (−0.45 – 0.56)
3.7 (1.1) 0.07 0.61 (0.29 – 0.79)
5.0 (0.2) 0.28 0.83 (0.70 – 0.91)
4.3 (0.7) 0.62 0.67 (0.40 – 0.82)
3.7 (0.8) 0.07 0.28 (−0.31 – 0.61)
3.6 (1.1) 0.29 0.44 (−0.33 – 0.69)
40.4 (5.4) 0.15 0.65 (0.57 – 0.71)
T intensity-modulated radiotherapy, MCO multicriteria optimization, PTV
t, CI confidence interval. Level of statistically significant differences was set to
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the 95% isodose line around both PTVs
– spinal cord maximum dose, parotid gland dose and
dose in unspecified tissue
– general plan quality
Additionally, general plan remarks were reported by
the ROs. After rating all conventional IMRT and MCO-
plans independently the plans were compared side-by-
side and the ROs’ preferred plan was determined for
each patient.
More quantitatively, plans were compared by means of
planning time, dose-volume parameters, conformity
index (CIV95%), and NTCP for xerostomia [16] and
physician-rated grade II-IV dysphagia [4]. The CIV95%
was defined as the ratio of the volume enclosed by the
95% isodose and the volume of the PTV that received at
least 95% of the prescription dose.
Statistical analysis
The inter-rater reliability was derived by the intra-class cor-
relation coefficient using a two-way random consistency
model (ICC [2,1], IBM SPSS Statistics version 22). Criteria
to interpret the ICC were set to: moderate (ICC values from
0.40 to 0.59), substantial (0.60 to 0.79), and almost perfect
(0.80 to 1.00). Statistically significant differences between
evaluation parameters were assessed using Wilcoxon
signed-rank test and considered statistically significant
at p < 0.05. For multiple structures a Bonferroni correc-
tion of p < 0.003 (α = 0.05/15 structures) was applied.
This study was granted exemption from our institution’s
ethical review board
Results
In total, the radiation-oncologists rated 800 items on
plan quality. The overall plan quality score indicates no
difference between conventional IMRT and MCO-plans
(conventional IMRT: 3.8 ± 1.2 vs. MCO: 3.6 ± 1.1, p =
0.29). The inter-rater reliability and the mean of the in-
dividual rated items are listed in Table 1. Dose cold
spots in the PTVboost were slightly lower rated for the
MCO-plans. However, all plans fulfilled the prescribedTable 2 Cross table indicating the plan quality scores for all i
Score MCO plans
1 2
Conventional IMRT plans 1 0 (0%) 2 (1%)
2 2 (1%) 13 (3%)
3 0 (0%) 6 (2%)
4 0 (0%) 9 (2%)
5 0 (0%) 7 (2%)
Total 2 (1%) 37 (9%)
The plan quality scores range from 1–5 with 5 the highest score.dose levels. Substantial to almost perfect agreement
among the ROs was observed for the following ratings:
dose cold spots in PTVprophylactic (ICC = 0.70), dose con-
formity around PTVprophylactic (ICC = 0.61), maximum
spinal cord dose (ICC = 0.83), and parotid gland dose
(ICC = 0.67). The majority of plan ratings (87%) were
within one-point difference between the ROs. In 1% of
the ratings there was less consensus (three-point differ-
ence). This was mainly caused by different scorings of
two conflicting parameters: dose conformity around the
PTV and parotid gland dose sparing. The inter-rater reli-
ability for all plan ratings was 0.65 (95% CI: 0.57–0.71),
indicating substantial agreement between the ROs.
The distribution of ratings between the conventional
IMRT and MCO-plans is shown in Table 2. Perfect
agreement was observed in 57% of all ratings. In 36% of
the cases the difference was one scored point. In 3% of
the rated items a three-point difference between the con-
ventional IMRT and MCO-plan was observed. Further-
more, the ROs selected the preferred plan (conventional
IMRT or MCO-plan) per patient as 60%: 40%, indicating a
slight preference for conventional IMRT.
Table 3 lists all dosimetric values, NTCP estimates,
plan evaluation parameters and statistical results. For
both the conventional IMRT and MCO-plans cumulative
DVHs as well as DVH difference maps of the PTVboost,
external (i.e. integral body dose), contra-lateral parotid
gland and the superior pharyngeal constrictor muscle
(PCM) are illustrated in Figure 1. A comparison of
DVHs for the two types of plans resulted in a p-value at
each dose level (Figure 1D). Furthermore, scatter plots
show the mean dose values of the given structures, the
D98% of both PTVs and the D2% of PTVboost, of the con-
ventional IMRT and MCO-plans (Figure 1E).
For the targets, MCO led to significantly lower vol-
umes receiving >73Gy (Figure 1 row I). Furthermore,
MCO-plans showed higher D98% and lower D2% values
for PTVboost, indicating increased target dose uni-
formity (Table 3). For the external the V<46Gy (i.e. the
relative volume receiving a dose of 46 Gy or less) and
the Dmean was significantly lower for the MCO-plans
(Figure 1 row II and Table 3). Also, steeper dose fall-tems of the conventional IMRT and MCO-plans
Total
3 4 5
1 (0%) 0 (0%) 0 (0%) 3 (1%)
12 (3%) 4 (1%) 3 (1%) 34 (9%)
9 (2%) 18 (5%) 7 (2%) 40 (10%)
28 (7%) 82 (21%) 18 (5%) 137 (34%)
8 (2%) 46 (12%) 125 (31%) 186 (47%)
58 (15%) 150 (38%) 153 (38%) 400 (100%)
Table 3 Plan evaluation parameters and dose statistics
Parameters Conventional IMRT MCO IMRT Difference p-value
Dose-volume values (Gy)
PTV (boost) D98% 66.4 ± 2.1 66.9 ± 1.1 −0.5 ± 0.5 0.03
PTV (boost) 70.2 ± 0.5 70.1 ± 0.3 0.2 ± 0.1 0.33
PTV (boost) D2% 73 ± 1.2 72.4 ± 0.7 0.6 ± 0.3 0.04
PTV (prophylactic) D98% 52 ± 0.7 52.5 ± 1.2 −0.4 ± 0.3 0.07
PTV (prophylactic) 54.6 ± 0.5 54.8 ± 1.0 −0.2 ± 0.2 0.53
Integral dose 13.9 ± 4.5 12.9 ± 4.0 0.9 ± 1.4 <0.001
Ring 1 cm around PTV 46.2 ± 2.6 45.0 ± 2.2 1.1 ± 0.8 0.008
Ring 6 cm around PTV 16.9 ± 3.2 15.0 ± 2.5 1.9 ± 0.9 <0.001
Spinal cord (D1%) 45.3 ± 3.9 44.1 ± 4.4 1.2 ± 1.3 0.17
Brain D1% 27.8 ± 14.5 27.5 ± 16.1 0.2 ± 4.8 0.31
Parotid gland (contra) 28.1 ± 11.8 23.0 ± 11.2 5.1 ± 8.1 <0.002
Parotid gland (ipsi) 39.1 ± 11.7 36.0 ± 11.1 3.0 ± 11.9 0.02
Superior PCM 58.8 ± 9.5 58.9 ± 10.2 −0.1 ± 3.1 0.91
Middle PCM 55.3 ± 14.0 56.3 ± 12.1 −1.0 ± 4.1 0.79
Inferior PCM 51.2 ± 16.8 52.2 ± 15.9 −1.0 ± 5.2 0.46
Supraglottic larynx 55.5 ± 15.3 57.3 ± 13.7 −1.9 ± 4.6 0.02
Esophagus inlet muscle 44.8 ± 12.2 44.1 ± 11.0 0.7 ± 3.7 0.28
Cricopharyngeus 48.6 ± 13.8 48.5 ± 13.6 0.1 ± 4.3 0.73
NTCP values (%)
Xerostomia [contra] 27.1 ± 20.9 18.7 ± 19.2 8.4 ± 7.4 <0.003
Xerostomia [ipsi] 48.2 ± 25.8 41.8 ± 24.0 6.4 ± 14.3 0.03
Dysphagia 35.4 ± 14.7 36.9 ± 14.7 −1.5 ± 4.7 0.11
Plan evaluation
CI 95% (PTV boost) 1.30 ± 0.12 1.28 ± 0.07 0.02 ± 0.03 0.98
CI 95% (PTV prophylactic) 1.54 ± 0.15 1.55 ± 0.13 −0.02 0.04 0.65
Monitor Units (#) 590 ± 135 672 ± 157 −82 ± 46 0.02
Total planning time (min) 205 43 ± 12 162 -
Abbreviations: PTV planning target volume, PCM pharyngeal constrictor muscle, NTCP normal tissue complication probability, CI 95% conformity index of 95%
isodose with PTV. Items with statistically significant differences (structure related: p < 0.003 else: p < 0.05) in bold.
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cated by the decreased mean dose to the 1 and 6 cm
ring structures (Table 3). The CI95% for both PTVs
showed no differences. The V>11Gy and the Dmean of
the contra-lateral parotid gland was significantly
lower for the MCO-plans (Figure 1 row III and
Table 3). For the superior PCM, the volume receiving
approximately 60 Gy slightly increased for the MCO-
plans (Figure 1 row IV).
The number of monitor units increased using MCO
planning (590 ± 135 vs. 672 ± 157, p = 0.02), indicating a
higher degree of intensity modulation (Table 3). How-
ever, decreased integral body dose was observed which
suggests that the MLC segments were generally smaller
in the MCO-plans. For the presented cases, predictions
of xerostomia were significantly lower (based on themean dose to the contra-lateral parotid gland: 8.4 ±
7.4%, p < 0.003) for the MCO-plans (Figure 2A and
Table 3). In contrast, NTCP-values for dysphagia were
similar between both planning techniques (Figure 2B).
However, this was expected, since no trade-off objec-
tives were used on the structures related to swallowing
dysfunction.
The hands-on time of the conventional IMRT plan-
ning was approximately 205 min, excluding time for
contouring. The planning time included: beam configur-
ation, planning parameter setup, generation of planning
support structures (e.g. ring structures), and the trial-
and-error inverse planning process. MCO planning took
on average 43 ± 12 min. The active planning time was
approximately 5 min for preparation and 20 min for
navigating the Pareto surface.
Figure 1 Colormap representation of cumulative DVHs of all patients (column A: MCO-plans and B: Conventional IMRT plans) and DVH difference
maps (column C, conventional IMRT minus MCO) for the PTVboost (row I), integral dose (i.e. External, row II), contra-lateral parotid gland (row III),
and superior pharyngeal constrictor muscle (PCM, row IV). Each row in the colormaps indicates the relative volume (difference) against dose for a
single patient. The vertical lines indicate the domain (*) at which the DVHs were significantly different. A comparison of DVHs for the conventional IMRT
and MCO-plans resulted in a p-value (Wilcoxon signed-rank test) at each dose level (column D). The orange and blue line sections indicate a
lower mean dose for the conventional IMRT or MCO-plans, respectively. The dotted line indicates the level of being statistically significant at
p = 0.05. The mean dose per structure and per planning technique is plotted in column E. Additionally, the D98% and D2% of PTVboost and
D98% of PTVprophylactic is shown. The mean dose of the contra-lateral and ipsi-lateral parotid glands are illustrated by circles and triangles,
respectively. The dashed line indicates the unity line.
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The increased demand of IMRT for different treatment
sites, as well as e.g. in-silico comparative planning stud-
ies, requires increased commitment of departmental re-
sources. In this study, we demonstrated that an MCO
system allows less experienced dosimetry planners to ef-
ficiently create high quality IMRT plans comparable to
conventionally optimized IMRT plans for HNC.
The MCO-plans were created by three novice treatment
planners. Prior to this study, these planners were intro-
duced to IMRT planning, including a practical exercise on
5 MCO cases. In contrast, the conventionally optimized
IMRT plans were created by multiple experienced IMRTplanners, therefore not biasing the results as if the plans
were created by one planner. Moreover, these plans were
representative of the plan quality within the department.
To assess the learning curve of MCO the quality of the
MCO plans as planned by the novice planners would pref-
erably be compared against MCO plans planned by experi-
enced MCO planners. Moreover, the learning curve for
MCO planning is relatively short, likely leading to a more
constant plan quality.
The quantitative dosimetric comparisons revealed re-
duced dose to the parotid glands, steeper dose fall-off
around the PTVs, and less integral body dose for the
MCO-plans. However, these findings were not observed
Figure 2 Normal tissue complication probability (NTCP) estimates for xerostomia (A) and physician-rated grade II-IV dysphagia (B). Xerostomia
NTCP values were derived for the contra- (circles) and ipsi-lateral (triangles) parotid glands.
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caused by the fact that all plans were blind-rated and
that the ROs were not aware of any further possible dose
reductions to critical regions. Furthermore, the dose to
the swallowing structures (e.g. supraglottic larynx and
pharyngeal constrictor muscles) slightly increased for
the MCO-plans. However, these structures were not
accounted for during planning optimization.
In 60% of cases the ROs selected the conventional
IMRT plans over the MCO-plan. For some cases the se-
lection was difficult because of the relatively small differ-
ences between the plans. Another reason for the RO of
not selecting the MCO-plans was the underdosage of
the PTV near the parotid glands for some plans. Slightly
changing the slider bars on the parotid gland trade-off
objectives would have resulted in different plans. Im-
proving target coverage near the parotid glands would
consequently deteriorate on parotid dose, and the pre-
sented NTCP-value reductions for xerostomia may be
too optimistic for some cases. Therefore, instructions to
the planner navigating the Pareto surface is crucial and
could lead to plans which are more preferred by the RO.
Moreover, the ROs may explore the Pareto surface, directly
selecting the preferred plan for the individual patient. This
benefit was discussed in more detail by Craft et al. [9].
In a number of cases, the MCO dose distribution quality
decreased after the conversion step of the navigated
fluence-based plan to a segmented machine deliverable
plan. This conversion step resulted in decreased target
coverage and increased dose to the OARs. To prevent the
decreased plan quality, Fredriksson and Bokrantz proposed
an approach to deliverable Pareto surface navigation, based
on subsets of apertures identical across plans [17]. The pro-
posed method is expected to lead to improved deliverable
treatment plans (i.e. what you see is what you get). In con-
ventional IMRT planning, on the other hand, decrease of
plan quality can also occur when the clinical dose calcula-
tion method is applied after optimization.It would be interesting to know if our findings are
generally valid and could also be obtained with other
MCO systems. The study of Craft et al. demonstrated
vastly reduced planning times and improved dose distri-
bution quality with MCO-plans for glioblastoma and
pancreatic cancers [9]. The total time spend by the treat-
ment planner and the RO was approximately 20 min.
Prostate treatment planning time with MCO took ap-
proximately 60 min per case [11]. In our study, the mean
planning time for HNC MCO planning was 43 min. The
difference is mainly caused by the difference in time to
create and navigate the Pareto plan library. Improvements
in computer architecture, e.g. by calculation on the GPU,
could reduce the time to create the Pareto plan library. In
the study of Craft et al. [9] the Pareto surface was navigated
by the physician, while in the study of Wala et al. [11] and
in ours, no physician was involved in the selection of the
final plan. The planning time with the MCO system was
considerably lower than the time required to create a con-
ventional IMRT plan (205 min). The latter was estimated
based on the current clinical workflow and therefore repre-
sentative for the included cases. Furthermore, this time was
comparable to the manual planning time (198 min) re-
ported by Voet et al. [10].
With interactive navigation across the Pareto surface
the understanding of the dosimetric options available
per patient will increase. This will hopefully lead to im-
proved dose distributions with lower NTCP estimates,
especially for HNC patients in which a relative high
number of OARs are in close vicinity of the targets.
Dose to these critical (sub)volumes may lead to a sub-
stantial variety of treatment-related adverse effects, such
as xerostomia and dysphagia [1]. For example, it has
been shown that long-term swallowing dysfunction after
HNC radiotherapy is related to the mean dose of the larynx
and pharyngeal musculature [4]. To reduce the correspond-
ing NTCP estimates without deteriorating on target cover-
age, dose should be optimally balanced among the related
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of multivariable NTCP models (including multiple
dose parameters and prognostic clinical factors) in the
optimization process facilitates individualized plan-
ning optimization in HNC [18]. To increase the MCO
performance, a slider based on multivariable NTCP
models would be preferred to find the optimal treat-
ment plan. Moreover, this would reduce the number
of currently used trade-off objectives to a few NTCP-
based objectives, simplifying the navigation process.
In conclusion, we demonstrated that MCO-plans for
HNC patients, created by novice dosimetry planners, result
in IMRT plans with increased target dose uniformity and
reduced dose to the parotid glands as compared to conven-
tionally planned IMRT. ROs blind-rated the MCO-plans of
similar quality as the conventional IMRT plans. Moreover,
the MCO planning required less resources and a short
learning curve. Therefore, MCO can serve as a promising
tool to efficiently use the departmental resources.
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